Gene symbol   |
Time course plot |
Accession |
Description |
Treatment |
15min |
30min |
1hr |
2hr |
4hr |
8hr |
20hr |
Ace | |
J04947 |
gb|Mouse angiotensin-converting enzyme mRNA, 3 end, clone ACE.11. [J04947] |
KLA | 1.06 |
1.03 |
1.08 |
1.11 |
1.10 |
.96 |
.91 |
| ATP | .99 |
1.11 |
.98 |
1.04 |
.99 |
1.06 |
1.00 |
| KLA/ATP | .91 |
.90 |
1.10 |
.98 |
.97 |
1.02 |
1.00 |
|
Ace | |
NM_009598 |
angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 (Ace), transcript variant 2, mRNA [NM_009598] |
KLA | 1.01 |
1.04 |
1.12 |
1.09 |
1.03 |
1.09 |
1.06 |
| ATP | .98 |
.99 |
1.09 |
1.15 |
1.02 |
1.02 |
1.07 |
| KLA/ATP | 1.06 |
1.08 |
1.05 |
1.10 |
1.09 |
1.02 |
1.00 |
|
Ace3 | |
NM_001101453 |
angiotensin I converting enzyme (peptidyl-dipeptidase A) 3 (Ace3), mRNA [NM_001101453] |
KLA | .97 |
1.06 |
1.03 |
1.00 |
1.00 |
1.06 |
1.01 |
| ATP | 1.01 |
.94 |
.98 |
1.03 |
.99 |
1.00 |
.97 |
| KLA/ATP | 1.04 |
.98 |
.96 |
1.04 |
1.01 |
1.12 |
1.02 |
|
Adcy1 | |
BC050125 |
adenylate cyclase 1, mRNA (cDNA clone IMAGE:30015692). [BC050125] |
KLA | 1.05 |
1.03 |
.98 |
1.04 |
1.05 |
1.09 |
1.10 |
| ATP | .90 |
1.02 |
.99 |
.97 |
1.03 |
.95 |
1.01 |
| KLA/ATP | .99 |
1.04 |
.90 |
.98 |
.98 |
1.00 |
1.03 |
|
Adcy1 | |
NM_009622 |
adenylate cyclase 1 (Adcy1), mRNA [NM_009622] |
KLA | 1.07 |
1.02 |
1.06 |
1.07 |
1.03 |
1.02 |
1.01 |
| ATP | 1.02 |
1.04 |
1.00 |
.99 |
.99 |
.95 |
.97 |
| KLA/ATP | .97 |
1.05 |
1.02 |
1.05 |
1.01 |
.98 |
1.05 |
|
Akt1 | |
NM_009652 |
thymoma viral proto-oncogene 1 (Akt1), mRNA [NM_009652] |
KLA | .80 |
.80 |
.75 |
.75 |
.71 |
.70 |
.82 |
| ATP | 1.00 |
1.02 |
.76 |
.85 |
.76 |
.68 |
.84 |
| KLA/ATP | .82 |
.80 |
.64 |
.68 |
.67 |
.61 |
.72 |
|
Akt2 | |
NM_007434 |
thymoma viral proto-oncogene 2 (Akt2), transcript variant 2, mRNA [NM_007434] |
KLA | 1.45 |
1.49 |
1.81 |
1.61 |
1.83 |
1.17 |
.92 |
| ATP | 1.12 |
1.12 |
1.00 |
1.28 |
1.20 |
.94 |
1.06 |
| KLA/ATP | 1.48 |
1.70 |
1.69 |
1.58 |
1.57 |
1.32 |
1.27 |
|
Akt3 | |
NM_011785 |
thymoma viral proto-oncogene 3 (Akt3), mRNA [NM_011785] |
KLA | 3.42 |
3.45 |
5.31 |
5.16 |
4.65 |
3.80 |
2.12 |
| ATP | 1.12 |
1.22 |
1.10 |
1.37 |
1.02 |
1.11 |
1.56 |
| KLA/ATP | 3.72 |
4.17 |
4.62 |
4.64 |
2.74 |
2.05 |
3.82 |
|
BI646741
| |
BI646741 |
gb|BI646741 603279769F1 NCI_CGAP_Mam3 Mus musculus cDNA clone IMAGE:5320025 5, mRNA sequence [BI646741] |
KLA | .55 |
.54 |
.47 |
.54 |
.65 |
1.09 |
1.60 |
| ATP | 1.04 |
.99 |
.93 |
1.08 |
2.49 |
.79 |
.88 |
| KLA/ATP | .54 |
.49 |
.54 |
.60 |
1.21 |
.97 |
1.54 |
|
Bdkrb2 | |
NM_009747 |
bradykinin receptor, beta 2 (Bdkrb2), mRNA [NM_009747] |
KLA | .97 |
.96 |
1.01 |
1.09 |
1.01 |
1.00 |
1.08 |
| ATP | 1.07 |
.98 |
1.04 |
1.01 |
1.05 |
1.00 |
1.08 |
| KLA/ATP | 1.02 |
1.05 |
1.04 |
1.01 |
1.03 |
1.04 |
.98 |
|
C1qa | |
NM_007572 |
complement component 1, q subcomponent, alpha polypeptide (C1qa), mRNA [NM_007572] |
KLA | 1.12 |
1.11 |
1.09 |
.94 |
1.11 |
1.12 |
1.31 |
| ATP | 1.14 |
1.21 |
.88 |
1.16 |
.90 |
.67 |
.95 |
| KLA/ATP | 1.12 |
1.23 |
.93 |
1.27 |
.86 |
.81 |
.91 |
|
C1qb | |
NM_009777 |
complement component 1, q subcomponent, beta polypeptide (C1qb), mRNA [NM_009777] |
KLA | 1.01 |
1.14 |
1.20 |
1.15 |
1.31 |
1.15 |
1.06 |
| ATP | 1.16 |
1.20 |
.84 |
1.27 |
1.02 |
.70 |
.76 |
| KLA/ATP | 1.29 |
1.36 |
.95 |
1.28 |
1.00 |
.97 |
.85 |
|
C1qc | |
NM_007574 |
complement component 1, q subcomponent, C chain (C1qc), mRNA [NM_007574] |
KLA | 1.03 |
.97 |
1.01 |
1.04 |
1.07 |
1.13 |
1.15 |
| ATP | 1.07 |
1.06 |
.91 |
.94 |
.77 |
.62 |
.82 |
| KLA/ATP | 1.08 |
1.02 |
.95 |
1.04 |
.76 |
.73 |
.66 |
|
C3 | |
NM_009778 |
complement component 3 (C3), mRNA [NM_009778] |
KLA | 28.58 |
25.57 |
24.39 |
27.34 |
23.38 |
23.21 |
18.10 |
| ATP | 1.04 |
.93 |
1.21 |
1.90 |
2.80 |
5.74 |
12.19 |
| KLA/ATP | 27.04 |
26.10 |
33.29 |
23.09 |
25.65 |
23.77 |
40.22 |
|
Calr | |
NM_007591 |
calreticulin (Calr), mRNA [NM_007591] |
KLA | .86 |
.95 |
1.00 |
.68 |
.92 |
.93 |
1.37 |
| ATP | 1.12 |
1.34 |
.91 |
1.33 |
1.07 |
.97 |
1.46 |
| KLA/ATP | 1.09 |
1.02 |
.63 |
1.06 |
.65 |
.92 |
1.16 |
|
Casp8 | |
NM_009812 |
caspase 8 (Casp8), transcript variant 1, mRNA [NM_009812] |
KLA | 2.41 |
2.53 |
3.20 |
3.26 |
2.75 |
2.78 |
1.57 |
| ATP | .91 |
.96 |
.66 |
.67 |
.54 |
1.53 |
1.52 |
| KLA/ATP | 2.47 |
2.52 |
2.08 |
2.41 |
1.41 |
2.50 |
2.77 |
|
Ccl12 | |
NM_011331 |
chemokine (C-C motif) ligand 12 (Ccl12), mRNA [NM_011331] |
KLA | 40.77 |
33.71 |
46.23 |
51.22 |
57.13 |
57.92 |
16.26 |
| ATP | 1.41 |
1.14 |
1.54 |
1.79 |
1.41 |
1.89 |
9.34 |
| KLA/ATP | 39.52 |
43.18 |
61.96 |
69.72 |
62.95 |
38.70 |
29.25 |
|
Ccl2 | |
NM_011333 |
chemokine (C-C motif) ligand 2 (Ccl2), mRNA [NM_011333] |
KLA | 10.26 |
9.30 |
8.35 |
10.02 |
8.92 |
14.08 |
11.59 |
| ATP | 1.62 |
1.68 |
2.20 |
4.16 |
3.92 |
4.84 |
17.45 |
| KLA/ATP | 10.09 |
10.31 |
10.95 |
12.32 |
8.00 |
10.04 |
21.29 |
|
Ccl3 | |
NM_011337 |
chemokine (C-C motif) ligand 3 (Ccl3), mRNA [NM_011337] |
KLA | 22.83 |
22.40 |
18.03 |
21.58 |
11.57 |
8.28 |
7.46 |
| ATP | 3.19 |
4.67 |
12.12 |
16.50 |
11.13 |
9.49 |
6.12 |
| KLA/ATP | 20.09 |
20.92 |
34.53 |
24.06 |
21.64 |
12.34 |
7.43 |
|
Ccl5 | |
M77747 |
rantes mRNA, complete cds. [M77747] |
KLA | 63.18 |
60.41 |
56.25 |
63.63 |
58.00 |
66.51 |
67.20 |
| ATP | .91 |
1.08 |
1.25 |
1.90 |
4.34 |
16.10 |
26.07 |
| KLA/ATP | 55.92 |
63.34 |
72.91 |
65.68 |
70.81 |
71.97 |
81.34 |
|
Ccl5 | |
NM_013653 |
chemokine (C-C motif) ligand 5 (Ccl5), mRNA [NM_013653] |
KLA | 40.31 |
35.22 |
27.92 |
38.59 |
29.29 |
37.98 |
28.83 |
| ATP | .86 |
.92 |
1.43 |
1.66 |
3.86 |
15.09 |
16.66 |
| KLA/ATP | 32.14 |
31.72 |
47.19 |
35.89 |
42.00 |
46.15 |
43.89 |
|
Cd247 | |
AK016078 |
adult male testis cDNA, RIKEN full-length enriched library, clone:4930549J05 product:unclassifiable, full insert sequence. [AK016078] |
KLA | .95 |
1.01 |
.98 |
1.08 |
1.01 |
.95 |
.99 |
| ATP | 1.01 |
1.05 |
1.02 |
.99 |
1.02 |
1.01 |
1.07 |
| KLA/ATP | .97 |
.99 |
1.00 |
1.05 |
1.01 |
.96 |
.98 |
|
Cd247 | |
NM_001113391 |
CD247 antigen (Cd247), transcript variant zeta, mRNA [NM_001113391] |
KLA | 3.06 |
3.63 |
3.61 |
2.90 |
3.04 |
1.93 |
1.28 |
| ATP | 1.07 |
1.03 |
1.19 |
1.21 |
1.39 |
1.42 |
1.12 |
| KLA/ATP | 3.09 |
3.74 |
2.98 |
2.90 |
2.14 |
2.13 |
2.41 |
|
Cd247 | |
NM_031162 |
CD247 antigen (Cd247), transcript variant eta, mRNA [NM_031162] |
KLA | 1.29 |
1.35 |
1.39 |
1.26 |
1.35 |
1.16 |
1.17 |
| ATP | .99 |
1.01 |
1.04 |
1.03 |
1.08 |
1.05 |
1.02 |
| KLA/ATP | 1.34 |
1.42 |
1.24 |
1.33 |
1.18 |
1.18 |
1.23 |
|
Cd3d | |
NM_013487 |
CD3 antigen, delta polypeptide (Cd3d), mRNA [NM_013487] |
KLA | 1.01 |
1.05 |
1.00 |
.95 |
.98 |
1.03 |
1.02 |
| ATP | 1.02 |
.94 |
1.08 |
.99 |
.99 |
.94 |
1.05 |
| KLA/ATP | .93 |
.91 |
.99 |
.98 |
.96 |
.96 |
1.04 |
|
Cd3e | |
NM_007648 |
CD3 antigen, epsilon polypeptide (Cd3e), mRNA [NM_007648] |
KLA | 1.21 |
1.25 |
1.29 |
1.22 |
1.29 |
1.32 |
1.13 |
| ATP | .98 |
1.00 |
1.10 |
1.11 |
1.10 |
1.19 |
1.11 |
| KLA/ATP | 1.24 |
1.30 |
1.32 |
1.30 |
1.22 |
1.19 |
1.10 |
|
Cd3g | |
NM_009850 |
CD3 antigen, gamma polypeptide (Cd3g), mRNA [NM_009850] |
KLA | 1.05 |
1.01 |
.96 |
1.01 |
1.02 |
.99 |
.99 |
| ATP | .94 |
.97 |
.99 |
.99 |
.95 |
1.02 |
1.07 |
| KLA/ATP | .95 |
.92 |
1.08 |
1.03 |
1.01 |
1.01 |
.99 |
|
Cflar | |
NM_009805 |
CASP8 and FADD-like apoptosis regulator (Cflar), transcript variant 2, mRNA [NM_009805] |
KLA | 18.63 |
20.03 |
20.30 |
17.44 |
17.99 |
11.88 |
7.25 |
| ATP | .95 |
1.03 |
1.20 |
2.78 |
4.04 |
3.45 |
3.30 |
| KLA/ATP | 19.31 |
19.09 |
11.65 |
13.57 |
7.62 |
6.20 |
11.21 |
|
Cflar | |
NM_207653 |
CASP8 and FADD-like apoptosis regulator (Cflar), transcript variant 1, mRNA [NM_207653] |
KLA | 12.32 |
12.86 |
11.83 |
11.79 |
12.14 |
8.52 |
5.42 |
| ATP | .92 |
.92 |
1.63 |
4.97 |
7.95 |
5.18 |
2.39 |
| KLA/ATP | 12.27 |
13.57 |
13.15 |
12.79 |
10.27 |
7.71 |
8.32 |
|
Cflar | |
Y14041 |
mRNA for CASH alpha protein. [Y14041] |
KLA | 14.31 |
13.82 |
13.05 |
13.06 |
14.36 |
9.02 |
5.92 |
| ATP | 1.18 |
1.15 |
1.66 |
6.44 |
8.99 |
5.20 |
2.73 |
| KLA/ATP | 15.53 |
17.07 |
14.00 |
17.10 |
10.76 |
8.02 |
9.97 |
|
Chuk | |
NM_007700 |
conserved helix-loop-helix ubiquitous kinase (Chuk), mRNA [NM_007700] |
KLA | 1.32 |
1.42 |
1.41 |
1.17 |
1.32 |
1.22 |
1.40 |
| ATP | 1.22 |
1.30 |
1.18 |
.97 |
1.02 |
1.00 |
1.37 |
| KLA/ATP | 1.56 |
1.61 |
1.21 |
1.09 |
.83 |
.84 |
1.17 |
|
Fadd | |
NM_010175 |
Fas (TNFRSF6)-associated via death domain (Fadd), mRNA [NM_010175] |
KLA | .54 |
.54 |
.59 |
.64 |
.80 |
.97 |
1.16 |
| ATP | 1.05 |
1.09 |
1.03 |
1.65 |
1.18 |
.78 |
1.61 |
| KLA/ATP | .56 |
.56 |
.53 |
.78 |
.78 |
.82 |
1.34 |
|
Fas | |
AK086933 |
0 day neonate lung cDNA, RIKEN full-length enriched library, clone:E030012O08 product:tumor necrosis factor receptor superfamily, member 6, full insert sequence. [AK086933] |
KLA | 6.31 |
6.56 |
6.33 |
6.70 |
4.93 |
3.74 |
2.48 |
| ATP | .95 |
1.04 |
1.33 |
1.55 |
1.85 |
6.00 |
2.77 |
| KLA/ATP | 5.67 |
7.16 |
7.71 |
7.73 |
6.02 |
5.79 |
7.85 |
|
Fas | |
NM_007987 |
Fas (TNF receptor superfamily member 6) (Fas), mRNA [NM_007987] |
KLA | 17.08 |
17.45 |
19.08 |
17.38 |
13.33 |
6.78 |
4.46 |
| ATP | .98 |
.96 |
1.64 |
3.05 |
5.58 |
12.91 |
1.89 |
| KLA/ATP | 16.57 |
17.25 |
26.06 |
23.57 |
22.03 |
16.74 |
13.29 |
|
Fasl | |
NM_010177 |
Fas ligand (TNF superfamily, member 6) (Fasl), mRNA [NM_010177] |
KLA | 1.03 |
1.01 |
1.03 |
1.02 |
1.01 |
1.01 |
1.00 |
| ATP | 1.00 |
.99 |
1.04 |
1.21 |
1.18 |
1.20 |
1.01 |
| KLA/ATP | 1.00 |
1.02 |
1.07 |
1.16 |
1.18 |
1.23 |
1.00 |
|
Fos | |
NM_010234 |
FBJ osteosarcoma oncogene (Fos), mRNA [NM_010234] |
KLA | .42 |
.33 |
.64 |
.61 |
.71 |
.85 |
.71 |
| ATP | 3.48 |
5.46 |
23.78 |
25.22 |
1.71 |
2.36 |
1.50 |
| KLA/ATP | .90 |
1.74 |
5.97 |
8.62 |
1.28 |
2.42 |
4.52 |
|
Gna11 | |
NM_010301 |
guanine nucleotide binding protein, alpha 11 (Gna11), mRNA [NM_010301] |
KLA | .62 |
.65 |
.69 |
.79 |
.94 |
1.00 |
.96 |
| ATP | 1.00 |
.94 |
.63 |
.53 |
.79 |
1.13 |
1.22 |
| KLA/ATP | .64 |
.60 |
.56 |
.55 |
.81 |
1.16 |
1.18 |
|
Gna14 | |
NM_008137 |
guanine nucleotide binding protein, alpha 14 (Gna14), mRNA [NM_008137] |
KLA | .97 |
.96 |
1.07 |
1.00 |
1.01 |
1.04 |
1.02 |
| ATP | .96 |
1.01 |
1.02 |
1.13 |
1.06 |
1.06 |
.96 |
| KLA/ATP | 1.03 |
.95 |
.93 |
1.06 |
1.13 |
1.10 |
1.05 |
|
Gna15 | |
NM_010304 |
guanine nucleotide binding protein, alpha 15 (Gna15), mRNA [NM_010304] |
KLA | 2.16 |
2.28 |
2.64 |
2.15 |
1.45 |
.98 |
.70 |
| ATP | .98 |
.89 |
.74 |
1.05 |
2.02 |
.97 |
1.07 |
| KLA/ATP | 2.18 |
2.11 |
1.63 |
1.66 |
1.69 |
1.17 |
.60 |
|
Gnai1 | |
NM_010305 |
guanine nucleotide binding protein (G protein), alpha inhibiting 1 (Gnai1), mRNA [NM_010305] |
KLA | .95 |
1.01 |
1.01 |
1.00 |
1.09 |
1.10 |
1.08 |
| ATP | 1.06 |
1.06 |
.99 |
1.15 |
1.02 |
.94 |
.99 |
| KLA/ATP | 1.02 |
1.04 |
.99 |
1.16 |
1.01 |
1.02 |
1.13 |
|
Gnai2 | |
NM_008138 |
guanine nucleotide binding protein (G protein), alpha inhibiting 2 (Gnai2), mRNA [NM_008138] |
KLA | .74 |
.79 |
.82 |
.74 |
.91 |
.97 |
1.10 |
| ATP | 1.07 |
1.16 |
.78 |
1.12 |
.78 |
.48 |
.82 |
| KLA/ATP | .91 |
.81 |
.53 |
.80 |
.60 |
.68 |
.87 |
|
Gnai3 | |
NM_010306 |
guanine nucleotide binding protein (G protein), alpha inhibiting 3 (Gnai3), mRNA [NM_010306] |
KLA | 1.23 |
1.24 |
1.14 |
1.06 |
.99 |
1.15 |
1.09 |
| ATP | .96 |
.93 |
.86 |
.64 |
1.34 |
2.02 |
1.35 |
| KLA/ATP | 1.20 |
1.24 |
.97 |
.76 |
1.21 |
1.62 |
1.17 |
|
Gnal | |
NM_010307 |
guanine nucleotide binding protein, alpha stimulating, olfactory type (Gnal), transcript variant 1, mRNA [NM_010307] |
KLA | 1.01 |
.90 |
.96 |
1.20 |
1.02 |
.97 |
.95 |
| ATP | .96 |
.92 |
.97 |
1.04 |
1.35 |
1.07 |
1.05 |
| KLA/ATP | .90 |
.98 |
.97 |
1.15 |
1.26 |
1.25 |
1.36 |
|
Gnao1 | |
NM_001113384 |
guanine nucleotide binding protein, alpha O (Gnao1), transcript variant B, mRNA [NM_001113384] |
KLA | .95 |
.98 |
1.03 |
1.00 |
1.02 |
1.02 |
.99 |
| ATP | .95 |
1.02 |
1.01 |
1.08 |
.99 |
.97 |
.95 |
| KLA/ATP | 1.05 |
1.04 |
1.10 |
.99 |
1.01 |
.98 |
1.03 |
|
Gnao1 | |
NM_010308 |
guanine nucleotide binding protein, alpha O (Gnao1), transcript variant A, mRNA [NM_010308] |
KLA | .98 |
.96 |
1.00 |
.97 |
.96 |
.97 |
1.01 |
| ATP | 1.12 |
.99 |
1.05 |
.87 |
.97 |
1.02 |
1.01 |
| KLA/ATP | .93 |
1.00 |
.99 |
1.01 |
1.05 |
1.07 |
.98 |
|
Gnaq | |
NM_008139 |
guanine nucleotide binding protein, alpha q polypeptide (Gnaq), mRNA [NM_008139] |
KLA | .82 |
.82 |
.69 |
.64 |
.60 |
.55 |
.55 |
| ATP | 1.06 |
1.02 |
.87 |
.67 |
.50 |
.66 |
.57 |
| KLA/ATP | .82 |
.79 |
.66 |
.55 |
.41 |
.33 |
.48 |
|
Gnas | |
AF107847 |
neuroendocrine-specific Golgi protein p55 isoform 1 (XLalphas) alternatively spliced mRNA, complete cds. [AF107847] |
KLA | 1.04 |
.94 |
1.00 |
1.05 |
1.04 |
.98 |
1.00 |
| ATP | .98 |
.97 |
.96 |
1.00 |
.99 |
.98 |
1.02 |
| KLA/ATP | 1.04 |
1.02 |
.96 |
.95 |
1.01 |
.96 |
1.01 |
|
Gnas | |
AK017423 |
10 days neonate head cDNA, RIKEN full-length enriched library, clone:5530400H20 product:novel noncoding RNA overlapping the exon 1A, 1 and 2 of Gnas, full insert sequence. [AK017423] |
KLA | .85 |
1.08 |
.97 |
.92 |
1.05 |
1.03 |
1.08 |
| ATP | .99 |
1.30 |
2.11 |
1.73 |
1.23 |
1.01 |
1.02 |
| KLA/ATP | .96 |
1.06 |
1.58 |
1.34 |
1.29 |
1.05 |
.91 |
|
Gnas | |
NM_001077510 |
GNAS (guanine nucleotide binding protein, alpha stimulating) complex locus (Gnas), transcript variant 8, mRNA [NM_001077510] |
KLA | .99 |
1.03 |
.97 |
.91 |
1.03 |
.95 |
.97 |
| ATP | 1.04 |
1.19 |
1.15 |
1.61 |
1.24 |
.91 |
1.00 |
| KLA/ATP | 1.06 |
.97 |
1.01 |
1.46 |
1.04 |
.85 |
1.01 |
|
Gnas | |
S49980 |
gb|stimulatory G protein alpha subunit {clone WC-16} [mice, whole cochlea, mRNA Partial, 356 nt]. [S49980] |
KLA | .91 |
.88 |
1.03 |
.87 |
.90 |
.84 |
1.01 |
| ATP | 1.16 |
1.22 |
1.02 |
1.55 |
1.16 |
.80 |
.99 |
| KLA/ATP | 1.01 |
1.13 |
.86 |
1.12 |
.97 |
.85 |
1.08 |
|
Ifnb1 | |
NM_010510 |
interferon beta 1, fibroblast (Ifnb1), mRNA [NM_010510] |
KLA | 49.82 |
46.57 |
34.05 |
16.05 |
5.94 |
7.31 |
8.49 |
| ATP | .99 |
1.02 |
1.89 |
4.78 |
6.31 |
4.44 |
1.79 |
| KLA/ATP | 49.22 |
61.83 |
134.08 |
144.05 |
110.96 |
31.78 |
11.24 |
|
Ifng | |
NM_008337 |
interferon gamma (Ifng), mRNA [NM_008337] |
KLA | 1.05 |
1.02 |
1.01 |
1.01 |
1.01 |
1.04 |
1.00 |
| ATP | 1.00 |
1.01 |
1.01 |
.98 |
.97 |
1.04 |
1.03 |
| KLA/ATP | 1.01 |
1.01 |
1.06 |
1.10 |
1.24 |
1.10 |
1.04 |
|
Ifngr1 | |
NM_010511 |
interferon gamma receptor 1 (Ifngr1), mRNA [NM_010511] |
KLA | .81 |
.60 |
.37 |
.35 |
.34 |
.39 |
.54 |
| ATP | 1.05 |
.96 |
1.15 |
.97 |
.80 |
.67 |
.45 |
| KLA/ATP | .57 |
.57 |
.63 |
.36 |
.28 |
.33 |
.36 |
|
Ifngr2 | |
NM_008338 |
interferon gamma receptor 2 (Ifngr2), mRNA [NM_008338] |
KLA | 1.45 |
1.49 |
1.74 |
2.22 |
3.22 |
2.42 |
1.96 |
| ATP | 1.11 |
1.03 |
.81 |
.78 |
1.12 |
1.28 |
1.34 |
| KLA/ATP | 1.48 |
1.41 |
1.17 |
1.23 |
1.48 |
1.89 |
2.13 |
|
Ikbkb | |
NM_010546 |
inhibitor of kappaB kinase beta (Ikbkb), mRNA [NM_010546] |
KLA | 1.88 |
2.10 |
2.14 |
1.83 |
1.73 |
1.31 |
1.19 |
| ATP | .81 |
.74 |
.55 |
.49 |
.59 |
1.05 |
.96 |
| KLA/ATP | 1.86 |
1.73 |
1.39 |
1.12 |
.89 |
1.17 |
1.24 |
|
Ikbkg | |
AK042138 |
3 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A630062P04 product:unclassifiable, full insert sequence. [AK042138] |
KLA | .92 |
.87 |
.78 |
.78 |
.87 |
.88 |
.62 |
| ATP | .84 |
.71 |
.80 |
.50 |
1.15 |
2.33 |
.61 |
| KLA/ATP | .72 |
.69 |
.74 |
.48 |
1.06 |
1.97 |
.68 |
|
Ikbkg | |
NM_010547 |
inhibitor of kappaB kinase gamma (Ikbkg), transcript variant 1, mRNA [NM_010547] |
KLA | 1.51 |
1.63 |
1.74 |
1.83 |
1.83 |
1.73 |
1.72 |
| ATP | .80 |
.79 |
.82 |
.75 |
.66 |
2.58 |
2.37 |
| KLA/ATP | 1.43 |
1.42 |
1.17 |
1.04 |
.71 |
1.54 |
3.17 |
|
Ikbkg | |
NM_178590 |
inhibitor of kappaB kinase gamma (Ikbkg), transcript variant 2, mRNA [NM_178590] |
KLA | .84 |
.93 |
.86 |
.91 |
1.03 |
.89 |
.88 |
| ATP | 1.03 |
.98 |
.68 |
.56 |
.51 |
.93 |
.68 |
| KLA/ATP | .89 |
.81 |
.55 |
.52 |
.41 |
.67 |
.65 |
|
Il10 | |
NM_010548 |
interleukin 10 (Il10), mRNA [NM_010548] |
KLA | 17.59 |
18.64 |
22.22 |
23.06 |
11.83 |
8.27 |
2.07 |
| ATP | 1.86 |
3.22 |
7.72 |
20.51 |
25.86 |
8.38 |
1.01 |
| KLA/ATP | 17.91 |
23.49 |
34.53 |
34.48 |
20.98 |
12.03 |
8.17 |
|
Il12a | |
NM_008351 |
interleukin 12a (Il12a), mRNA [NM_008351] |
KLA | 2.37 |
2.47 |
2.17 |
1.49 |
1.46 |
1.12 |
1.20 |
| ATP | 1.01 |
.97 |
1.12 |
1.07 |
1.02 |
1.07 |
1.06 |
| KLA/ATP | 2.01 |
2.76 |
2.54 |
1.70 |
1.08 |
1.10 |
1.27 |
|
Il12b | |
NM_008352 |
interleukin 12b (Il12b), mRNA [NM_008352] |
KLA | 194.79 |
211.32 |
198.97 |
173.01 |
142.24 |
40.28 |
3.10 |
| ATP | 1.05 |
1.10 |
1.59 |
1.99 |
2.71 |
2.72 |
1.52 |
| KLA/ATP | 191.27 |
223.23 |
280.10 |
224.29 |
183.03 |
68.43 |
10.69 |
|
Il1b | |
NM_008361 |
interleukin 1 beta (Il1b), mRNA [NM_008361] |
KLA | 149.78 |
133.59 |
100.91 |
116.58 |
86.48 |
89.37 |
64.72 |
| ATP | 3.49 |
13.96 |
61.44 |
70.91 |
82.12 |
162.79 |
28.18 |
| KLA/ATP | 130.32 |
139.00 |
219.12 |
148.17 |
165.44 |
172.57 |
146.98 |
|
Il2 | |
NM_008366 |
interleukin 2 (Il2), mRNA [NM_008366] |
KLA | .96 |
.97 |
.96 |
1.00 |
.97 |
.97 |
.99 |
| ATP | 1.04 |
1.02 |
1.00 |
1.03 |
.97 |
.98 |
.97 |
| KLA/ATP | 1.01 |
.98 |
.97 |
1.00 |
.97 |
.97 |
.96 |
|
Il6 | |
NM_031168 |
interleukin 6 (Il6), mRNA [NM_031168] |
KLA | 352.99 |
378.70 |
276.81 |
168.47 |
59.99 |
18.66 |
8.27 |
| ATP | 1.04 |
1.08 |
2.28 |
3.69 |
30.40 |
161.93 |
2.11 |
| KLA/ATP | 334.28 |
528.66 |
###.## |
935.86 |
302.45 |
355.36 |
99.65 |
|
Irak1 | |
NM_008363 |
interleukin-1 receptor-associated kinase 1 (Irak1), mRNA [NM_008363] |
KLA | .67 |
.67 |
.64 |
.56 |
.58 |
.58 |
.84 |
| ATP | 1.02 |
1.10 |
.94 |
1.14 |
.81 |
.54 |
.87 |
| KLA/ATP | .72 |
.72 |
.57 |
.67 |
.51 |
.43 |
.62 |
|
Irak4 | |
NM_029926 |
interleukin-1 receptor-associated kinase 4 (Irak4), mRNA [NM_029926] |
KLA | .82 |
.86 |
.78 |
.82 |
.95 |
1.21 |
1.22 |
| ATP | 1.02 |
1.18 |
.95 |
1.10 |
.79 |
.85 |
.82 |
| KLA/ATP | .86 |
.89 |
.77 |
.90 |
.78 |
.96 |
.88 |
|
Jun | |
NM_010591 |
Jun oncogene (Jun), mRNA [NM_010591] |
KLA | 1.08 |
.96 |
1.09 |
1.09 |
.75 |
.88 |
.81 |
| ATP | 1.26 |
1.48 |
4.45 |
8.73 |
4.02 |
1.16 |
1.99 |
| KLA/ATP | 1.12 |
1.38 |
3.52 |
5.17 |
3.32 |
.49 |
1.42 |
|
Map2k4 | |
NM_009157 |
mitogen-activated protein kinase kinase 4 (Map2k4), mRNA [NM_009157] |
KLA | 3.67 |
3.75 |
4.23 |
3.90 |
3.30 |
1.87 |
1.12 |
| ATP | 1.05 |
1.11 |
1.04 |
.93 |
1.16 |
2.62 |
1.02 |
| KLA/ATP | 3.70 |
4.13 |
3.27 |
4.13 |
2.98 |
3.03 |
1.82 |
|
Mapk1 | |
NM_001038663 |
mitogen-activated protein kinase 1 (Mapk1), transcript variant 2, mRNA [NM_001038663] |
KLA | .97 |
1.03 |
.93 |
.86 |
.79 |
1.01 |
1.04 |
| ATP | .96 |
1.18 |
1.01 |
1.13 |
.84 |
1.04 |
1.16 |
| KLA/ATP | .99 |
.99 |
.84 |
.87 |
.63 |
.96 |
1.26 |
|
Mapk1 | |
NM_011949 |
mitogen-activated protein kinase 1 (Mapk1), transcript variant 1, mRNA [NM_011949] |
KLA | .88 |
.80 |
.80 |
.73 |
.75 |
.76 |
.65 |
| ATP | .97 |
.96 |
1.06 |
.88 |
.90 |
.68 |
.48 |
| KLA/ATP | .82 |
.81 |
.78 |
.65 |
.64 |
.64 |
.45 |
|
Mapk10 | |
AK076990 |
adult male testis cDNA, RIKEN full-length enriched library, clone:4930597C01 product:mitogen activated protein kinase 10, full insert sequence. [AK076990] |
KLA | 1.03 |
1.05 |
.98 |
1.04 |
.94 |
.95 |
1.02 |
| ATP | 1.00 |
.99 |
1.06 |
.97 |
1.01 |
.96 |
.99 |
| KLA/ATP | 1.07 |
1.01 |
.95 |
1.05 |
.82 |
.95 |
.87 |
|
Mapk10 | |
NM_009158 |
mitogen-activated protein kinase 10 (Mapk10), transcript variant 1, mRNA [NM_009158] |
KLA | .95 |
1.00 |
.97 |
1.01 |
.99 |
1.01 |
.95 |
| ATP | 1.01 |
1.02 |
.98 |
1.01 |
1.04 |
1.01 |
.99 |
| KLA/ATP | 1.05 |
.99 |
1.01 |
.98 |
.92 |
.97 |
.98 |
|
Mapk11 | |
NM_011161 |
mitogen-activated protein kinase 11 (Mapk11), mRNA [NM_011161] |
KLA | 1.28 |
1.30 |
1.41 |
1.46 |
1.58 |
1.29 |
.98 |
| ATP | .96 |
.95 |
.89 |
.82 |
.79 |
1.09 |
.85 |
| KLA/ATP | 1.44 |
1.42 |
1.32 |
1.23 |
1.23 |
.74 |
.66 |
|
Mapk12 | |
NM_013871 |
mitogen-activated protein kinase 12 (Mapk12), mRNA [NM_013871] |
KLA | .94 |
.86 |
.87 |
.81 |
.77 |
.68 |
.49 |
| ATP | .97 |
.83 |
.92 |
.90 |
.86 |
.90 |
.51 |
| KLA/ATP | .91 |
.89 |
.88 |
.85 |
1.12 |
1.14 |
.53 |
|
Mapk13 | |
NM_011950 |
mitogen-activated protein kinase 13 (Mapk13), mRNA [NM_011950] |
KLA | 1.22 |
1.21 |
1.35 |
1.26 |
1.24 |
1.13 |
1.01 |
| ATP | 1.08 |
1.00 |
1.20 |
1.20 |
1.13 |
1.22 |
1.39 |
| KLA/ATP | 1.22 |
1.27 |
1.30 |
1.30 |
1.21 |
1.11 |
1.47 |
|
Mapk14 | |
NM_011951 |
mitogen-activated protein kinase 14 (Mapk14), mRNA [NM_011951] |
KLA | .70 |
.70 |
.62 |
.54 |
.67 |
.88 |
1.11 |
| ATP | 1.03 |
.98 |
.87 |
.69 |
.48 |
.78 |
.66 |
| KLA/ATP | .74 |
.68 |
.52 |
.46 |
.38 |
.45 |
.62 |
|
Mapk3 | |
NM_011952 |
mitogen-activated protein kinase 3 (Mapk3), mRNA [NM_011952] |
KLA | .81 |
.85 |
.88 |
.72 |
.79 |
.73 |
.90 |
| ATP | 1.13 |
1.30 |
.92 |
1.48 |
1.08 |
.68 |
1.03 |
| KLA/ATP | 1.01 |
1.01 |
.66 |
1.13 |
.77 |
.77 |
1.16 |
|
Mapk8 | |
AK162915 |
adult male spinal cord cDNA, RIKEN full-length enriched library, clone:A330031O19 product:mitogen activated protein kinase 8, full insert sequence [AK162915] |
KLA | .94 |
.86 |
.80 |
.83 |
.77 |
.85 |
.83 |
| ATP | 1.08 |
1.12 |
.94 |
.80 |
.83 |
.71 |
.75 |
| KLA/ATP | .83 |
.81 |
.80 |
.74 |
.74 |
.75 |
.67 |
|
Mapk8 | |
AK163829 |
16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130070A06 product:mitogen activated protein kinase 8, full insert sequence [AK163829] |
KLA | .65 |
.61 |
.66 |
.70 |
.90 |
1.02 |
1.03 |
| ATP | .99 |
.94 |
1.68 |
1.44 |
1.75 |
1.84 |
1.10 |
| KLA/ATP | .63 |
.67 |
1.11 |
1.00 |
2.01 |
1.68 |
1.15 |
|
Mapk8 | |
NM_016700 |
mitogen-activated protein kinase 8 (Mapk8), mRNA [NM_016700] |
KLA | .96 |
1.00 |
.94 |
.96 |
.94 |
.99 |
1.04 |
| ATP | 1.01 |
1.05 |
1.01 |
.99 |
1.03 |
.98 |
1.02 |
| KLA/ATP | .96 |
.97 |
.96 |
.97 |
.93 |
.94 |
.96 |
|
Mapk9 | |
NM_016961 |
mitogen-activated protein kinase 9 (Mapk9), transcript variant 2, mRNA [NM_016961] |
KLA | 1.28 |
1.37 |
1.59 |
1.60 |
1.61 |
1.43 |
1.38 |
| ATP | 1.03 |
.99 |
.74 |
.71 |
.79 |
1.20 |
1.01 |
| KLA/ATP | 1.53 |
1.30 |
1.07 |
.99 |
.83 |
1.10 |
1.40 |
|
Mapk9 | |
NM_207692 |
mitogen-activated protein kinase 9 (Mapk9), transcript variant 1, mRNA [NM_207692] |
KLA | 1.39 |
1.53 |
1.69 |
1.69 |
1.55 |
1.44 |
1.51 |
| ATP | .95 |
.92 |
.75 |
.85 |
.70 |
1.46 |
1.17 |
| KLA/ATP | 1.37 |
1.35 |
.99 |
1.18 |
.91 |
1.22 |
1.62 |
|
Mm.21036 1 | |
158508719 |
Unknown |
KLA | 1.12 |
1.15 |
1.09 |
1.20 |
1.18 |
1.33 |
1.23 |
| ATP | 1.05 |
1.18 |
1.10 |
1.41 |
1.26 |
1.25 |
1.23 |
| KLA/ATP | 1.22 |
1.40 |
1.22 |
1.54 |
1.24 |
1.28 |
1.49 |
|
Mm.21312 8 | |
141801344 |
Unknown |
KLA | .96 |
.95 |
.83 |
.77 |
.52 |
.99 |
1.32 |
| ATP | .80 |
.82 |
1.09 |
.80 |
.83 |
1.19 |
1.46 |
| KLA/ATP | .78 |
.92 |
.98 |
.62 |
.71 |
.94 |
1.41 |
|
Mm.24936 4 | |
133892283 |
Unknown |
KLA | 1.42 |
1.41 |
1.61 |
2.14 |
2.88 |
2.49 |
2.03 |
| ATP | .98 |
.98 |
.76 |
.77 |
1.09 |
1.23 |
1.28 |
| KLA/ATP | 1.32 |
1.32 |
1.07 |
1.12 |
1.38 |
1.85 |
1.95 |
|
Mm.25381 9 | |
118130676 |
Unknown |
KLA | 1.81 |
1.88 |
1.96 |
1.62 |
1.89 |
2.44 |
1.56 |
| ATP | .92 |
.91 |
1.24 |
1.01 |
1.16 |
2.06 |
1.95 |
| KLA/ATP | 1.62 |
1.86 |
1.86 |
1.41 |
1.89 |
2.37 |
1.97 |
|
Mm.27970
| |
13994135 |
Unknown |
KLA | 1.06 |
1.11 |
1.16 |
1.07 |
1.11 |
1.08 |
.95 |
| ATP | 1.02 |
1.09 |
1.05 |
1.05 |
.94 |
1.16 |
1.32 |
| KLA/ATP | 1.10 |
1.19 |
1.11 |
1.04 |
1.08 |
1.02 |
1.33 |
|
Mm.29669 9 | |
82935400 |
Unknown |
KLA | 1.02 |
1.02 |
1.14 |
1.10 |
1.03 |
1.14 |
1.02 |
| ATP | .98 |
1.05 |
1.17 |
1.14 |
1.08 |
1.04 |
1.01 |
| KLA/ATP | 1.13 |
1.11 |
1.17 |
1.11 |
1.06 |
1.09 |
1.04 |
|
Mm.38049
| |
118130391 |
Unknown |
KLA | .67 |
.65 |
.73 |
.92 |
.63 |
.81 |
.76 |
| ATP | .93 |
.92 |
1.08 |
.54 |
.45 |
1.48 |
1.56 |
| KLA/ATP | .57 |
.65 |
.98 |
.67 |
.44 |
.78 |
1.16 |
|
Mm.41292 2 | |
145966829 |
Unknown |
KLA | 3.65 |
3.76 |
3.75 |
3.79 |
3.42 |
1.75 |
1.10 |
| ATP | 1.11 |
1.17 |
1.04 |
.90 |
1.37 |
2.90 |
1.00 |
| KLA/ATP | 3.31 |
3.97 |
3.38 |
3.84 |
3.04 |
3.31 |
2.09 |
|
Mm.44160 1 | |
145966786 |
Unknown |
KLA | 1.08 |
.94 |
1.01 |
.97 |
.79 |
.78 |
.71 |
| ATP | 1.09 |
.92 |
1.10 |
.75 |
.65 |
.92 |
.69 |
| KLA/ATP | 1.01 |
.92 |
1.16 |
.81 |
.69 |
.56 |
.63 |
|
Mm.44889
| |
157057165 |
Unknown |
KLA | 1.20 |
1.25 |
1.45 |
1.49 |
1.63 |
1.70 |
1.66 |
| ATP | 1.00 |
1.03 |
1.03 |
1.00 |
1.12 |
1.06 |
1.23 |
| KLA/ATP | 1.25 |
1.15 |
1.16 |
1.16 |
1.15 |
1.41 |
1.71 |
|
Mm.46002 4 | |
38348245 |
Unknown |
KLA | 1.22 |
1.25 |
1.25 |
1.19 |
1.22 |
1.47 |
1.14 |
| ATP | 1.03 |
.94 |
1.01 |
1.01 |
2.67 |
2.31 |
1.37 |
| KLA/ATP | 1.35 |
1.19 |
1.27 |
1.22 |
1.99 |
1.83 |
1.45 |
|
Mm.5126 | |
158508678 |
Unknown |
KLA | .70 |
.71 |
.73 |
.79 |
.87 |
1.11 |
1.25 |
| ATP | 1.22 |
1.37 |
1.08 |
1.54 |
1.38 |
1.01 |
1.26 |
| KLA/ATP | .85 |
.83 |
.75 |
.90 |
1.12 |
.96 |
1.17 |
|
Mm.874 | |
6754317 |
Unknown |
KLA | 24.98 |
24.87 |
26.43 |
39.61 |
12.88 |
8.64 |
1.63 |
| ATP | 1.97 |
3.50 |
11.05 |
28.47 |
38.30 |
10.44 |
.65 |
| KLA/ATP | 23.45 |
29.37 |
58.52 |
51.77 |
30.64 |
14.61 |
8.63 |
|
Myd88 | |
NM_010851 |
myeloid differentiation primary response gene 88 (Myd88), mRNA [NM_010851] |
KLA | 3.35 |
3.51 |
3.91 |
4.13 |
4.13 |
3.62 |
2.53 |
| ATP | .99 |
.96 |
.79 |
.75 |
.93 |
2.15 |
1.60 |
| KLA/ATP | 3.37 |
3.52 |
3.52 |
3.48 |
2.81 |
3.03 |
3.33 |
|
Nfkb1 | |
BC050841 |
nuclear factor of kappa light chain gene enhancer in B-cells 1, p105, mRNA (cDNA clone IMAGE:6392793), complete cds. [BC050841] |
KLA | 5.81 |
4.96 |
4.77 |
3.21 |
3.37 |
2.00 |
1.71 |
| ATP | 1.39 |
1.52 |
3.25 |
12.63 |
13.64 |
4.80 |
1.08 |
| KLA/ATP | 7.21 |
8.69 |
19.53 |
23.93 |
11.70 |
2.85 |
2.01 |
|
Nfkb1 | |
M57999 |
gb|Mouse transcription factor NF-kappa-B DNA binding subunit mRNA, complete cds. [M57999] |
KLA | 8.55 |
7.87 |
7.35 |
6.13 |
3.51 |
1.85 |
1.38 |
| ATP | .98 |
.96 |
1.21 |
3.06 |
5.29 |
4.67 |
.69 |
| KLA/ATP | 7.32 |
7.20 |
8.71 |
10.82 |
5.55 |
2.77 |
1.54 |
|
Nfkbia | |
NM_010907 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (Nfkbia), mRNA [NM_010907] |
KLA | 18.65 |
18.46 |
13.63 |
17.88 |
14.25 |
9.17 |
7.92 |
| ATP | .91 |
1.09 |
7.11 |
32.39 |
17.44 |
10.49 |
1.72 |
| KLA/ATP | 15.57 |
17.66 |
15.73 |
23.91 |
13.83 |
10.73 |
9.48 |
|
Nos2 | |
NM_010927 |
nitric oxide synthase 2, inducible, macrophage (Nos2), mRNA [NM_010927] |
KLA | 13.50 |
16.36 |
25.65 |
23.25 |
24.78 |
15.99 |
6.48 |
| ATP | 1.03 |
1.03 |
1.48 |
1.66 |
1.65 |
5.55 |
1.70 |
| KLA/ATP | 16.01 |
17.41 |
19.06 |
25.50 |
20.84 |
29.92 |
29.80 |
|
Pik3ca | |
ENSMUST00000108243 |
ens|Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (EC 2.7.1.153) (PI3-kinase p110 subunit alpha) (PtdIns-3- kinase p110) (PI3K). [Source:Uniprot/SWISSPROT;Acc:P42337] [ENSMUST00000108243] |
KLA | 1.07 |
1.01 |
.91 |
.90 |
.98 |
.96 |
.86 |
| ATP | 1.03 |
.87 |
1.12 |
.63 |
1.22 |
1.86 |
.60 |
| KLA/ATP | 1.05 |
.82 |
.91 |
.61 |
1.17 |
1.26 |
.63 |
|
Pik3ca | |
NM_008839 |
phosphatidylinositol 3-kinase, catalytic, alpha polypeptide (Pik3ca), mRNA [NM_008839] |
KLA | 1.15 |
1.11 |
1.05 |
.82 |
.99 |
1.03 |
1.27 |
| ATP | .98 |
1.00 |
.79 |
.75 |
.96 |
1.32 |
1.10 |
| KLA/ATP | 1.10 |
.98 |
.64 |
.72 |
.80 |
1.20 |
1.41 |
|
Pik3cb | |
NM_029094 |
phosphatidylinositol 3-kinase, catalytic, beta polypeptide (Pik3cb), mRNA [NM_029094] |
KLA | 1.06 |
1.06 |
1.03 |
.73 |
.68 |
.98 |
1.69 |
| ATP | 1.04 |
1.21 |
.95 |
1.02 |
.85 |
.93 |
1.73 |
| KLA/ATP | 1.15 |
1.27 |
.73 |
.83 |
.58 |
.81 |
1.81 |
|
Pik3cd | |
NM_008840 |
phosphatidylinositol 3-kinase catalytic delta polypeptide (Pik3cd), transcript variant 1, mRNA [NM_008840] |
KLA | 2.28 |
2.42 |
3.10 |
4.17 |
3.35 |
2.31 |
1.34 |
| ATP | 1.02 |
.91 |
.99 |
.63 |
.30 |
.67 |
.80 |
| KLA/ATP | 2.14 |
2.23 |
2.70 |
1.51 |
1.17 |
.85 |
.72 |
|
Pik3cd | |
U86587 |
phosphatidylinositol 3-kinase catalytic subunit p110 delta mRNA, complete cds. [U86587] |
KLA | 2.21 |
2.24 |
3.71 |
3.17 |
3.67 |
2.66 |
1.48 |
| ATP | 1.00 |
1.03 |
.93 |
.96 |
.46 |
.75 |
.97 |
| KLA/ATP | 2.27 |
2.32 |
1.97 |
2.02 |
1.01 |
.99 |
.98 |
|
Pik3cg | |
NM_020272 |
phosphoinositide-3-kinase, catalytic, gamma polypeptide (Pik3cg), mRNA [NM_020272] |
KLA | .53 |
.53 |
.61 |
.64 |
.97 |
.86 |
.79 |
| ATP | 1.01 |
1.13 |
.88 |
.89 |
.52 |
.53 |
.53 |
| KLA/ATP | .58 |
.53 |
.43 |
.60 |
.40 |
.43 |
.62 |
|
Pik3r1 | |
NM_001077495 |
phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha) (Pik3r1), transcript variant 2, mRNA [NM_001077495] |
KLA | 1.05 |
1.07 |
1.03 |
1.00 |
1.01 |
1.20 |
.85 |
| ATP | .97 |
1.02 |
1.48 |
1.42 |
1.76 |
1.33 |
1.23 |
| KLA/ATP | 1.11 |
1.12 |
1.06 |
1.17 |
1.24 |
.99 |
1.12 |
|
Pik3r2 | |
NM_008841 |
phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 2 (p85 beta) (Pik3r2), mRNA [NM_008841] |
KLA | .50 |
.50 |
.48 |
.43 |
.46 |
.66 |
.75 |
| ATP | .78 |
.68 |
.45 |
.43 |
.28 |
.57 |
1.37 |
| KLA/ATP | .49 |
.38 |
.32 |
.33 |
.38 |
.67 |
1.10 |
|
Pik3r3 | |
NM_181585 |
phosphatidylinositol 3 kinase, regulatory subunit, polypeptide 3 (p55) (Pik3r3), mRNA [NM_181585] |
KLA | 1.59 |
1.49 |
1.37 |
1.17 |
1.05 |
1.55 |
1.41 |
| ATP | 1.12 |
1.00 |
1.33 |
1.70 |
2.01 |
2.37 |
2.02 |
| KLA/ATP | 1.63 |
1.54 |
1.58 |
1.70 |
2.43 |
2.68 |
1.92 |
|
Pik3r5 | |
NM_177320 |
phosphoinositide-3-kinase, regulatory subunit 5, p101 (Pik3r5), mRNA [NM_177320] |
KLA | 3.57 |
3.58 |
4.16 |
3.54 |
4.11 |
2.59 |
2.39 |
| ATP | 1.08 |
1.08 |
.93 |
1.67 |
3.11 |
1.88 |
1.34 |
| KLA/ATP | 3.91 |
3.70 |
3.30 |
3.80 |
2.70 |
2.04 |
3.00 |
|
Plcb1 | |
AK129166 |
mRNA for mKIAA0581 protein [AK129166] |
KLA | 1.02 |
.98 |
.91 |
.91 |
.92 |
.95 |
.89 |
| ATP | 1.03 |
1.02 |
1.02 |
1.01 |
.90 |
1.02 |
1.04 |
| KLA/ATP | .98 |
.97 |
.91 |
.93 |
.92 |
1.01 |
1.16 |
|
Plcb1 | |
NM_019677 |
phospholipase C, beta 1 (Plcb1), mRNA [NM_019677] |
KLA | .99 |
.94 |
.95 |
.97 |
.93 |
.92 |
.91 |
| ATP | 1.00 |
.96 |
.99 |
.95 |
.99 |
1.03 |
.98 |
| KLA/ATP | .93 |
.96 |
.94 |
.93 |
.87 |
1.00 |
1.06 |
|
Plcb2 | |
NM_177568 |
phospholipase C, beta 2 (Plcb2), mRNA [NM_177568] |
KLA | .70 |
.68 |
.64 |
.67 |
.65 |
.76 |
.88 |
| ATP | .95 |
.94 |
1.04 |
.94 |
.72 |
.57 |
1.19 |
| KLA/ATP | .69 |
.68 |
.72 |
.63 |
.65 |
.55 |
.70 |
|
Plcb3 | |
NM_008874 |
phospholipase C, beta 3 (Plcb3), mRNA [NM_008874] |
KLA | 1.72 |
1.78 |
1.82 |
1.65 |
1.67 |
1.44 |
1.21 |
| ATP | .97 |
1.04 |
.81 |
.87 |
.78 |
.88 |
.94 |
| KLA/ATP | 1.69 |
1.89 |
1.44 |
1.66 |
1.12 |
.73 |
.93 |
|
Plcb4 | |
AK082509 |
0 day neonate cerebellum cDNA, RIKEN full-length enriched library, clone:C230058B11 product:unclassifiable, full insert sequence. [AK082509] |
KLA | 1.06 |
1.03 |
.97 |
.98 |
1.02 |
1.01 |
.99 |
| ATP | .99 |
1.07 |
1.09 |
.95 |
.97 |
.97 |
1.02 |
| KLA/ATP | .98 |
1.00 |
1.03 |
.96 |
1.02 |
.91 |
.98 |
|
Plcb4 | |
NM_013829 |
phospholipase C, beta 4 (Plcb4), mRNA [NM_013829] |
KLA | .88 |
.94 |
.81 |
.82 |
.81 |
.86 |
1.01 |
| ATP | 1.00 |
1.01 |
.92 |
.93 |
.88 |
.85 |
.89 |
| KLA/ATP | .97 |
.94 |
.78 |
.80 |
.78 |
.86 |
.97 |
|
Ppp2ca | |
NM_019411 |
protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform (Ppp2ca), mRNA [NM_019411] |
KLA | 1.17 |
1.13 |
1.18 |
1.20 |
1.54 |
1.45 |
1.34 |
| ATP | 1.09 |
1.20 |
1.07 |
1.33 |
1.56 |
2.04 |
1.43 |
| KLA/ATP | 1.14 |
1.17 |
1.15 |
1.49 |
1.59 |
2.37 |
2.02 |
|
Ppp2cb | |
NM_017374 |
protein phosphatase 2 (formerly 2A), catalytic subunit, beta isoform (Ppp2cb), mRNA [NM_017374] |
KLA | 1.32 |
1.33 |
1.37 |
1.24 |
1.27 |
1.09 |
1.18 |
| ATP | .94 |
.93 |
.82 |
.91 |
1.22 |
2.01 |
1.08 |
| KLA/ATP | 1.24 |
1.14 |
.80 |
.97 |
1.13 |
1.54 |
1.18 |
|
Ppp2r1a | |
NM_016891 |
protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65), alpha isoform (Ppp2r1a), mRNA [NM_016891] |
KLA | 1.44 |
1.39 |
1.47 |
1.37 |
1.69 |
1.33 |
1.16 |
| ATP | 1.18 |
1.55 |
.85 |
1.67 |
1.38 |
.99 |
1.24 |
| KLA/ATP | 1.66 |
1.98 |
.97 |
2.33 |
1.41 |
1.65 |
1.38 |
|
Ppp2r1b | |
NM_001034085 |
protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65), beta isoform (Ppp2r1b), transcript variant 1, mRNA [NM_001034085] |
KLA | 1.26 |
1.17 |
1.14 |
1.13 |
1.12 |
1.11 |
.99 |
| ATP | .90 |
.90 |
.96 |
.98 |
1.59 |
1.71 |
1.16 |
| KLA/ATP | 1.23 |
1.16 |
.99 |
1.00 |
1.54 |
1.34 |
1.24 |
|
Ppp2r1b | |
NM_028614 |
protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65), beta isoform (Ppp2r1b), transcript variant 2, mRNA [NM_028614] |
KLA | 2.38 |
2.38 |
2.53 |
1.80 |
1.52 |
.95 |
1.16 |
| ATP | 1.17 |
1.29 |
1.04 |
1.09 |
1.16 |
1.19 |
1.00 |
| KLA/ATP | 2.59 |
2.78 |
1.82 |
2.31 |
1.34 |
1.03 |
.75 |
|
Ppp2r2a | |
NM_028032 |
protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), alpha isoform (Ppp2r2a), mRNA [NM_028032] |
KLA | 2.18 |
2.42 |
2.58 |
2.17 |
2.08 |
1.83 |
1.57 |
| ATP | 1.06 |
1.12 |
.90 |
1.28 |
1.76 |
1.70 |
1.39 |
| KLA/ATP | 2.55 |
2.38 |
1.62 |
2.68 |
2.25 |
2.55 |
1.86 |
|
Ppp2r2b | |
AK086561 |
15 days embryo head cDNA, RIKEN full-length enriched library, clone:D930037C08 product:unclassifiable, full insert sequence [AK086561] |
KLA | .94 |
1.02 |
1.07 |
1.02 |
1.02 |
.97 |
.98 |
| ATP | 1.01 |
1.04 |
1.01 |
.99 |
.97 |
.95 |
1.00 |
| KLA/ATP | 1.04 |
1.06 |
1.01 |
.96 |
1.02 |
.90 |
.93 |
|
Ppp2r2b | |
NM_028392 |
protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), beta isoform (Ppp2r2b), transcript variant 2, mRNA [NM_028392] |
KLA | 1.01 |
1.02 |
.96 |
1.00 |
1.04 |
1.01 |
1.00 |
| ATP | 1.00 |
.96 |
1.07 |
.93 |
.95 |
1.01 |
1.03 |
| KLA/ATP | .95 |
1.01 |
1.06 |
1.07 |
.98 |
1.02 |
1.03 |
|
Ppp2r2c | |
NM_172994 |
protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), gamma isoform (Ppp2r2c), mRNA [NM_172994] |
KLA | .97 |
.98 |
.96 |
1.02 |
1.02 |
1.06 |
1.01 |
| ATP | .96 |
1.05 |
1.03 |
.98 |
1.01 |
1.04 |
1.06 |
| KLA/ATP | .98 |
.98 |
1.00 |
.96 |
1.00 |
.86 |
1.10 |
|
Ppp2r2d | |
NM_026391 |
protein phosphatase 2, regulatory subunit B, delta isoform (Ppp2r2d), mRNA [NM_026391] |
KLA | 1.07 |
1.03 |
1.14 |
1.18 |
1.16 |
1.27 |
1.13 |
| ATP | .96 |
.93 |
.95 |
.76 |
1.34 |
2.21 |
1.22 |
| KLA/ATP | 1.01 |
1.01 |
1.01 |
.87 |
1.91 |
2.19 |
2.18 |
|
Rela | |
NM_009045 |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) (Rela), mRNA [NM_009045] |
KLA | 2.05 |
2.05 |
2.07 |
1.75 |
1.83 |
1.58 |
1.33 |
| ATP | 1.03 |
1.08 |
1.10 |
1.44 |
1.61 |
2.48 |
1.05 |
| KLA/ATP | 2.17 |
2.27 |
2.05 |
2.47 |
1.93 |
2.35 |
2.02 |
|
Serpine1
| |
AK040662 |
adult male aorta and vein cDNA, RIKEN full-length enriched library, clone:A530009B11 product:serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1, full insert sequence. [AK040662] |
KLA | 1.12 |
1.08 |
1.10 |
1.03 |
1.00 |
1.01 |
1.05 |
| ATP | 1.00 |
1.09 |
1.39 |
1.44 |
1.05 |
.95 |
.99 |
| KLA/ATP | 1.09 |
1.10 |
1.02 |
1.03 |
1.08 |
1.19 |
1.02 |
|
Serpine1
| |
NM_008871 |
serine (or cysteine) peptidase inhibitor, clade E, member 1 (Serpine1), mRNA [NM_008871] |
KLA | 36.00 |
31.05 |
27.47 |
23.20 |
11.59 |
4.14 |
1.47 |
| ATP | .97 |
1.15 |
3.43 |
11.58 |
8.77 |
7.42 |
2.16 |
| KLA/ATP | 31.47 |
33.70 |
38.54 |
30.90 |
22.06 |
23.68 |
18.57 |
|
Smad2 | |
NM_010754 |
MAD homolog 2 (Drosophila) (Smad2), mRNA [NM_010754] |
KLA | 1.05 |
1.08 |
1.04 |
1.17 |
1.40 |
1.43 |
1.59 |
| ATP | 1.01 |
1.02 |
1.16 |
1.14 |
1.15 |
1.32 |
1.34 |
| KLA/ATP | 1.00 |
.99 |
.97 |
1.09 |
1.40 |
1.14 |
1.40 |
|
Smad3 | |
NM_016769 |
MAD homolog 3 (Drosophila) (Smad3), mRNA [NM_016769] |
KLA | .64 |
.60 |
.57 |
.64 |
.70 |
1.25 |
1.52 |
| ATP | 1.02 |
1.02 |
.84 |
1.21 |
2.42 |
.90 |
1.19 |
| KLA/ATP | .64 |
.60 |
.65 |
.66 |
1.29 |
1.26 |
2.26 |
|
Tgfb1 | |
NM_011577 |
transforming growth factor, beta 1 (Tgfb1), mRNA [NM_011577] |
KLA | .87 |
.89 |
.90 |
.70 |
.83 |
.77 |
1.12 |
| ATP | 1.20 |
1.41 |
.80 |
1.49 |
1.11 |
.93 |
.99 |
| KLA/ATP | 1.10 |
1.20 |
.53 |
1.05 |
.66 |
.85 |
.90 |
|
Tgfb2 | |
NM_009367 |
transforming growth factor, beta 2 (Tgfb2), mRNA [NM_009367] |
KLA | 1.01 |
.91 |
.98 |
.98 |
.92 |
1.19 |
.96 |
| ATP | .99 |
1.03 |
1.00 |
1.02 |
.99 |
1.07 |
.93 |
| KLA/ATP | 1.02 |
.99 |
1.03 |
.98 |
1.04 |
1.06 |
.96 |
|
Tgfb3 | |
NM_009368 |
transforming growth factor, beta 3 (Tgfb3), mRNA [NM_009368] |
KLA | .67 |
.64 |
.58 |
.56 |
.49 |
.52 |
.61 |
| ATP | .90 |
.92 |
1.33 |
1.08 |
.78 |
.65 |
.74 |
| KLA/ATP | .58 |
.60 |
.74 |
.61 |
.76 |
1.36 |
1.51 |
|
Tgfbr1 | |
NM_009370 |
transforming growth factor, beta receptor I (Tgfbr1), mRNA [NM_009370] |
KLA | .73 |
.74 |
.59 |
.54 |
.52 |
.64 |
.84 |
| ATP | .99 |
1.12 |
.99 |
1.16 |
1.22 |
.84 |
.93 |
| KLA/ATP | .75 |
.78 |
.58 |
.64 |
.62 |
.59 |
.77 |
|
Tgfbr2 | |
AK090393 |
10 days pregnant adult female ovary and uterus cDNA, RIKEN full-length enriched library, clone:G630098D03 product:transforming growth factor, beta receptor II, full insert sequence. [AK090393] |
KLA | .98 |
.89 |
1.00 |
.96 |
.94 |
1.00 |
.92 |
| ATP | .99 |
.99 |
.90 |
.94 |
.93 |
.96 |
1.02 |
| KLA/ATP | .92 |
.96 |
.98 |
.98 |
.98 |
.95 |
1.01 |
|
Tgfbr2 | |
NM_009371 |
transforming growth factor, beta receptor II (Tgfbr2), transcript variant 1, mRNA [NM_009371] |
KLA | .55 |
.50 |
.58 |
.50 |
.52 |
.55 |
.44 |
| ATP | .98 |
.75 |
.50 |
.32 |
.41 |
.29 |
.50 |
| KLA/ATP | .59 |
.45 |
.32 |
.23 |
.31 |
.27 |
.25 |
|
Tgfbr2 | |
NM_029575 |
transforming growth factor, beta receptor II (Tgfbr2), transcript variant 2, mRNA [NM_029575] |
KLA | .95 |
.93 |
.99 |
.95 |
.88 |
1.02 |
.82 |
| ATP | .87 |
.93 |
.84 |
.84 |
.74 |
.72 |
1.00 |
| KLA/ATP | .89 |
.85 |
.83 |
.85 |
.76 |
.80 |
.79 |
|
Ticam1 | |
NM_174989 |
toll-like receptor adaptor molecule 1 (Ticam1), mRNA [NM_174989] |
KLA | 1.45 |
1.63 |
2.02 |
2.36 |
3.12 |
2.34 |
2.21 |
| ATP | 1.16 |
1.19 |
.90 |
2.58 |
4.78 |
2.04 |
1.80 |
| KLA/ATP | 1.79 |
1.71 |
1.07 |
2.89 |
5.60 |
3.26 |
3.50 |
|
Tlr2 | |
NM_011905 |
toll-like receptor 2 (Tlr2), mRNA [NM_011905] |
KLA | 13.65 |
11.82 |
8.87 |
7.95 |
4.67 |
2.78 |
2.33 |
| ATP | 1.06 |
1.24 |
2.76 |
6.28 |
11.55 |
13.82 |
.67 |
| KLA/ATP | 13.11 |
12.91 |
14.48 |
13.84 |
14.18 |
11.14 |
2.78 |
|
Tlr4 | |
NM_021297 |
toll-like receptor 4 (Tlr4), mRNA [NM_021297] |
KLA | .69 |
.61 |
.75 |
.94 |
.64 |
.81 |
.73 |
| ATP | .95 |
.90 |
1.12 |
.56 |
.47 |
1.51 |
1.53 |
| KLA/ATP | .57 |
.62 |
1.01 |
.64 |
.39 |
.73 |
1.13 |
|
Tlr6 | |
NM_011604 |
toll-like receptor 6 (Tlr6), mRNA [NM_011604] |
KLA | 6.41 |
6.63 |
6.53 |
6.69 |
4.70 |
4.27 |
2.63 |
| ATP | 1.04 |
.95 |
1.02 |
.65 |
1.11 |
5.02 |
3.78 |
| KLA/ATP | 6.27 |
6.99 |
7.49 |
5.08 |
4.10 |
4.69 |
7.46 |
|
Tlr9 | |
NM_031178 |
toll-like receptor 9 (Tlr9), mRNA [NM_031178] |
KLA | 1.08 |
1.09 |
1.18 |
1.15 |
1.34 |
1.25 |
1.16 |
| ATP | 1.04 |
1.05 |
1.23 |
1.85 |
1.41 |
1.06 |
1.21 |
| KLA/ATP | 1.16 |
1.17 |
1.45 |
1.88 |
1.67 |
1.32 |
1.46 |
|
Tnf | |
NM_013693 |
tumor necrosis factor (Tnf), mRNA [NM_013693] |
KLA | 13.35 |
12.76 |
10.71 |
9.03 |
10.64 |
7.39 |
8.32 |
| ATP | 2.01 |
2.48 |
8.27 |
19.20 |
9.72 |
4.09 |
1.49 |
| KLA/ATP | 12.72 |
15.76 |
12.73 |
17.34 |
5.10 |
3.61 |
6.07 |
|
Tnfrsf1a
| |
NM_011609 |
tumor necrosis factor receptor superfamily, member 1a (Tnfrsf1a), mRNA [NM_011609] |
KLA | 1.74 |
1.71 |
1.90 |
2.16 |
1.95 |
1.74 |
1.16 |
| ATP | .95 |
.83 |
.55 |
.41 |
.41 |
1.55 |
1.32 |
| KLA/ATP | 1.58 |
1.49 |
1.19 |
1.03 |
.98 |
2.02 |
2.10 |
|
Traf6 | |
NM_009424 |
Tnf receptor-associated factor 6 (Traf6), mRNA [NM_009424] |
KLA | 1.19 |
1.28 |
1.34 |
1.20 |
1.23 |
1.23 |
1.28 |
| ATP | 1.06 |
1.12 |
.92 |
1.15 |
2.46 |
1.84 |
1.40 |
| KLA/ATP | 1.32 |
1.37 |
.89 |
1.16 |
1.45 |
1.49 |
1.46 |
|